With first FDA approval under its belt, Shorla Oncology raises $35M


Seven months after netting its first FDA approval, Shorla Oncology, a biotech startup with roots in Ireland, is putting $35 million toward growing its Cambridge presence.

Previous Moderna's combination Covid-and-flu shot shows promise in midstage study
Next Jacksonville housing market gains $7 billion in value